Department of Medicine, University of Pennsylvania, Philadelphia, PA.
Division of Transplant Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA.
Transplantation. 2021 Aug 1;105(8):1800-1807. doi: 10.1097/TP.0000000000003417.
There is no unified consensus as to the preferred immunosuppression (IS) strategy following liver retransplantation (reLT).
This was a retrospective cohort study using the United Network for Organ Sharing database. Recipient, donor, and center characteristics associated with induction use and early maintenance IS regimen were described. Multivariable Cox proportional hazards analysis evaluated induction receipt as a predictor of post-reLT survival.
There were 3483 adult reLT recipients from 2002 to 2018 at 116 centers with 95.6% being performed at the same center as the initial liver transplant. Timing of reLT was associated with induction IS use and the discharge regimen (P < 0.001 for both) but not with regimens at 6- and 12-month post-reLT (P = 0.1 for both). Among late reLTs (>365 d), initial liver disease cause was a more important determinant of maintenance regimen than graft failure cause. Low-reLT volume centers used induction more often for late reLTs (41.1% versus 22.6% high volume; P = 0.002) yet were less likely to wean to calcineurin inhibitors alone in the first year (19.1% versus 38.7% high volume; P = 0.002). Accounting for recipient and donor factors, depleting induction marginally improved post-reLT mortality (adjusted hazard ratio, 0.77; 95% CI, 0.61-0.99; P = 0.08), whereas nondepleting induction had no significant effect.
Although several recipient attributes inform early IS decision-making, this does not occur in a uniform manner and center factors also play a role. Further studies are needed to assess the effect of early IS on post-reLT outcomes.
肝移植后(reLT)的首选免疫抑制(IS)策略尚未达成统一共识。
这是一项使用 United Network for Organ Sharing 数据库的回顾性队列研究。描述了与诱导使用和早期维持 IS 方案相关的受者、供者和中心特征。多变量 Cox 比例风险分析评估了诱导接受作为 reLT 后生存的预测因素。
2002 年至 2018 年,在 116 个中心进行了 3483 例成人 reLT 受者,其中 95.6%在与初始肝移植相同的中心进行。reLT 的时机与诱导 IS 的使用和出院方案相关(均 P < 0.001),但与 reLT 后 6 个月和 12 个月的方案无关(均 P = 0.1)。在晚期 reLT(>365 d)中,初始肝病的病因比移植物衰竭的病因更能决定维持方案。低 reLT 量中心更常为晚期 reLT 使用诱导(41.1%与高容量的 22.6%;P = 0.002),但在第一年更不可能单独转为钙调神经磷酸酶抑制剂(19.1%与高容量的 38.7%;P = 0.002)。在考虑受者和供者因素后,耗竭诱导剂可轻微改善 reLT 后的死亡率(调整后的危险比,0.77;95%CI,0.61-0.99;P = 0.08),而非耗竭诱导剂则无显著效果。
尽管有几个受者特征可以帮助确定早期 IS 决策,但这种决策方式并不统一,中心因素也发挥了作用。需要进一步研究来评估早期 IS 对 reLT 后结果的影响。